Huaan Securities released a research report on April 17 stating that it gave Innote (688253.SH) a buy rating. The main reasons for the rating include: 1) extremely high revenue and profit growth, with core revenue +205% in 23; 2) profit release due to COVID-19 clearance, 1Q24 net profit +171%; 3) clinical guidelines urge accurate screening of respiratory pathogens and proper medication use. (Mainichi Keizai Shimbun)
华安证券4月17日发布研报称，给予英诺特（688253.SH）买入评级。评级理由主要包括：1）收入利润超高增长，23年核心收入+205%；2）新冠出清带来利润释放，1Q24归母净利润+171%；3）临床指南敦促对呼吸道病原体精确筛查，正确用药。（每日经济新闻）
Huaan Securities released a research report on April 17 stating that it gave Innote (688253.SH) a buy rating. The main reasons for the rating include: 1) extremely high revenue and profit growth, with core revenue +205% in 23; 2) profit release due to COV
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.